Cover Image

A randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation-positive NSCLC patients

The hepatocyte growth factor receptor mesenchymal-epithelial transition (MET) is reported to be a negative prognostic marker in EGFR-mutant NSCLC and involved in resistance to EGFR inhibitors. Emibetuzumab, a humanized immunoglobulin G4 monoclonal bivalent MET antibody, blocks ligand-dependent and l...

Full description

Saved in:
Bibliographic Details
Main Authors: Scagliotti, Giorgio V. (Author) , Moro-Sibilot, Denis (Author) , Kollmeier, Jens (Author) , Favaretto, Adolfo (Author) , Cho, Eun Kyung (Author) , Grosch, Heidrun (Author) , Kimmich, Martin (Author) , Girard, Nicolas (Author) , Tsai, Chun-Ming (Author) , Hsia, Te-Chun (Author) , Brighenti, Matteo (Author) , Schumann, Christian (Author) , Wang, Xuejing Aimee (Author) , Wijayawardana, Sameera R. (Author) , Gruver, Aaron M. (Author) , Wallin, Johan (Author) , Mansouri, Kambiz (Author) , Wacheck, Volker (Author) , Chang, Gee-Chen (Author)
Format: Article (Journal)
Language:English
Published: 2020
In: Journal of thoracic oncology
Year: 2019, Volume: 15, Issue: 1, Pages: 80-90
ISSN:1556-1380
DOI:10.1016/j.jtho.2019.10.003
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jtho.2019.10.003
Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S1556086419335300
Get full text
Author Notes:Giorgio Scagliotti, Denis Moro-Sibilot, Jens Kollmeier, Adolfo Favaretto, Eun Kyung Cho, Heidrun Grosch, Martin Kimmich, Nicolas Girard, Chun-Ming Tsai, Te-Chun Hsia, Matteo Brighenti, Christian Schumann, Xuejing Aimee Wang, Sameera R. Wijayawardana, Aaron M. Gruver, Johan Wallin, Kambiz Mansouri, Volker Wacheck, Gee-Chen Chang
Description
Summary:The hepatocyte growth factor receptor mesenchymal-epithelial transition (MET) is reported to be a negative prognostic marker in EGFR-mutant NSCLC and involved in resistance to EGFR inhibitors. Emibetuzumab, a humanized immunoglobulin G4 monoclonal bivalent MET antibody, blocks ligand-dependent and ligand-independent hepatocyte growth factor/MET signaling. This phase 2 study compared erlotinib with and without emibetuzumab in first-line treatment of EGFR-mutant metastatic NSCLC.
Item Description:Available online - 14 October 2019
Gesehen am 11.03.2020
Physical Description:Online Resource
ISSN:1556-1380
DOI:10.1016/j.jtho.2019.10.003

Similar Items